Colin Broom MD

All filings by Colin Broom MD on record concern Nabriva Therapeutics plc, in the capacity of board member. In total, 15 filings cover trades dated from 23 June 2017 to 2 August 2022.

Both buying and selling appear: 4 purchases worth €92k, against 4 sales worth €27k. Netting one side against the other leaves €66k of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 3 share grants and 2 option exercises. 2022 to date brings no purchases and 1 sale.

Half of the purchases are above €18k and half below. Of 4 purchases, 4 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The newest entry dates from 4 August 2022: an open-market sale of €1,000, in Nabriva Therapeutics plc. The last purchase on record was published on 3 September 2019, which is 2,607 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.